Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer (ASCO) Basic Listing

Updates in Non-Small Cell Lung Cancer
From the ASCO Annual Meeting

David Spigel, MD, Sarah Cannon Research Institute
Videos
Molecular Assay May Predict Patients With Non-Small Cell Lung Cancer to Benefit From Adjuvant Therapy
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
APP Institute Oncology
Conference Coverage
Asandeutertinib for Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer
05/27/2025
Allison Casey
According to a phase 2 study, asandeutertinib showed efficacy and tolerable safety among patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer and brain metastases.
According to a phase 2 study, asandeutertinib showed efficacy and tolerable safety among patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer and brain metastases.
According to a phase 2 study,...
05/27/2025
Oncology
Conference Coverage
Patritumab Deruxtecan for Patients With Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer
05/27/2025
Allison Casey
Results from the phase 3 HERTHENA-Lung02 trial found patritumab deruxtecan had a statistically significant improvement in progression-free survival compared to platinum-based chemotherapy among patients with EGFR-mutant non-small cell lung...
Results from the phase 3 HERTHENA-Lung02 trial found patritumab deruxtecan had a statistically significant improvement in progression-free survival compared to platinum-based chemotherapy among patients with EGFR-mutant non-small cell lung...
Results from the phase 3...
05/27/2025
Oncology
Conference Coverage
Plasma-Guided Adaptive Chemoimmunotherapy for Patients With First-Line Non-Small Cell Lung Cancer
05/27/2025
Allison Casey
According to a prospective clinical trial, the use of plasma-guided adaptive treatment led to a median progression-free survival comparable to historical controls for patients with advanced PD-L1–positive non-small cell lung cancer.
According to a prospective clinical trial, the use of plasma-guided adaptive treatment led to a median progression-free survival comparable to historical controls for patients with advanced PD-L1–positive non-small cell lung cancer.
According to a prospective...
05/27/2025
Oncology
Conference Coverage
Zipalertinib Shows Response, Safety for Patients With Previously Treated NSCLC and EGFR Exon 20 Insertion Mutations
05/27/2025
Allison Casey
According to a phase 2b trial, zipalertinib showed clinically meaningful efficacy and manageable safety among patients with NSCLC and exon 20 insertion mutations who had previously been treated with platinum-based chemotherapy with or without...
According to a phase 2b trial, zipalertinib showed clinically meaningful efficacy and manageable safety among patients with NSCLC and exon 20 insertion mutations who had previously been treated with platinum-based chemotherapy with or without...
According to a phase 2b trial,...
05/27/2025
Oncology
Suresh Ramalingam, MD
Conference Coverage
Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer
06/02/2024
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed...
06/02/2024
Oncology
Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Videos
Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
07/17/2023
Paul K. Paik, MD
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer
07/17/2023
Ticiana Leal, MD
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Roy Herbst, MD, PhD, Yale Cancer Center
Videos
Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC
06/19/2023
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
06/19/2023
Oncology
Sunvozertinib Demonstrates Superior Antitumor Efficacy Over Current Available Therapy for NSCLC With EGFR Exon20 Insertion Mutations
06/19/2023
Stephanie Holland
Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.
Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.
Results from the phase 2...
06/19/2023
Oncology

Recent News

News
Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer
09/12/2025
Stephanie Holland
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy...
09/12/2025
Oncology
News
Durvalumab Plus Platinum-Based Chemotherapy for Treatment-Naive Patients With Extensive-Stage Small Cell Lung Cancer
09/10/2025
Stephanie Holland
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...
According to exploratory...
09/10/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer
09/10/2025
Stephanie Holland
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.
According to results from a...
09/10/2025
Oncology
FDA Approval
FDA Approves Selumetinib Granules and Capsules for Pediatric Patients With NF1-Associated Symptomatic and Inoperable Plexiform Neurofibromas
09/10/2025
Stephanie Holland
The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.
The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.
The FDA has approved selumetinib...
09/10/2025
Oncology
News
Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.
According to results from a...
08/28/2025
Oncology
News
Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
08/28/2025
Stephanie Holland
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.
According to results from the...
08/28/2025
Oncology
News
Dual Immune Checkpoint Blockade Plus Radiotherapy Fails to Improve Outcomes Among Newly Diagnosed Patients With MGMT-Unmethylated Glioblastoma
08/28/2025
Stephanie Holland
According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...
According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...
According to results from a...
08/28/2025
Oncology
News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology
News
Afatinib Plus Carboplatin and Pemetrexed Demonstrates Efficacy, Safety Among Patients WIth Advanced EGFR-Mutated Non-Small Cell Lung Cancer
08/27/2025
Stephanie Holland
According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...
According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...
According to results from the...
08/27/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use